超声治疗对冠心病患者血浆GMP-140及vWF的影响及意义

Influence of Ultrasonic Therapy on Plasma GMP-140 and vWF in Patients with Coronary Heart Disease

【目的】探讨超声治疗对冠心病患者GMP-140及vWF的影响及意义。【方法】选用未使用抗血小板药物的冠心病患者70例随机分为超声联合药物治疗组(超声组)35例和常规药物治疗组(药物组)35例,观察治疗前后vWF和GMP-140的变化,采用硝酸还原酶法和ELISA双抗体夹心法测定治疗前后GMP-140和vWF含量。【结果】与治疗前相比,治疗后两组患者GMP-140和vWF水平明显下降,超声组治疗前后比较P<0.01;药物组治疗前后比较vWFP<0.01,GMP-140P<0.05,超声组比药物组患者GMP-140和vWF水平下降更明显P<0.05。【结论】冠心病患者体内存在血小板活化,血小板活化参与了冠心病的发展过程,超声治疗冠心病的机制与超声的三大生物效应外还与降低血浆GMP-140和vWF浓度,减少粘附反应等多种因素共同作用的结果。

[Objective] To study the influence of ultrasonic therapy on plasma granule membrane protein- 140（GMP-140） and yon Willebrand factor（vWF） in patients with coronary heart disease（CHD）. [Methods] Plasma GMP-140 and vWF in patients with CHD who had no anti-platelet treatment but ultrasonic therapy were measured by the method of nitrate reductase and sandwich ELISA before and after therapy respectively. [Results]The levels of plasma GMP-140 and vWF declined in two groups. And plasma GMP-140 and vWF in ultrasonic group decreased obviously more than those in the control group. [Conclusion] These findings indi- cate that platelet activation is associated with atherosclerosis and pathophysiologic progress of CHD. And the mechanism of ultrasonic therapy for CHD may be related to the effects of GMP-140 and vWF.